# Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

> **NCT00525031** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 55 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Temozolomide (TMZ)
- **DRUG:** Pegylated Interferon Alpha-2b (PGI)

## Key facts

- **NCT ID:** NCT00525031
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525031, "Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00525031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*